Table 2

Progression to HGD/OAC for the three review diagnosis categories in patients with available endoscopic follow-up

LGD
(n=75)
IND
(n=36)
NDBO
(n=153)
Number of patients with HGD/OAC21 (27%)1 (3%)4 (2%)
HGD/OAC incidence per patient-year (95% CI)9.1% (5.8 to 13.6)0.9% (0.4 to 4.3)0.6% (0.2 to 1.3)
2-Year cumulative risk of HGD/OAC (95% CI)16.7% (7.5 to 25.9)2.9% (0.0 to 8.4)0.0% (0.0 to 2.4)
5-Year cumulative risk of HGD/OAC (95% CI)33.3% (18.2 to 48.4)2.9% (0.0 to 8.4)2.1% (0.0 to 5.0)
  • HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; NDBO, non-dysplastic Barrett's oesophagus; OAC, oesophageal adenocarcinoma.